Successful live attenuated vaccines mimic natural exposure to pathogens without causing disease and have been successful against several viruses. However, safety concerns prevent the development of attenuated human immunodeficiency virus (HIV) as a vaccine candidate. If a safe, replicating virus vaccine could be developed, it might have the potential to offer significant protection against HIV infection and disease. Described here is the development of a novel self-replicating chimeric virus vaccine candidate that is designed to provide natural exposure to a lentivirus-like particle and to incorporate the properties of a live attenuated virus vaccine without the inherent safety issues associated with attenuated lentiviruses. The genome from the alphavirus Venezuelan equine encephalitis virus (VEE) was modified to express SHIV89.6P genes encoding the structural proteins Gag and Env. Expression of Gag and Env from VEE RNA in primate cells led to the assembly of particles that morphologically and functionally resembled lentivirus virions and that incorporated alphavirus RNA. Infection of CD4 ؉ cells with chimeric lentivirus-like particles was specific and productive, resulting in RNA replication, expression of Gag and Env, and generation of progeny chimeric particles. Further genome modifications designed to enhance encapsidation of the chimeric virus genome and to express an attenuated simian immunodeficiency virus (SIV) protease for particle maturation improved the ability of chimeric lentivirus-like particles to propagate in cell culture. This study provides proof of concept for the feasibility of creating chimeric virus genomes that express lentivirus structural proteins and assemble into infectious particles for presentation of lentivirus immunogens in their native and functional conformation.
T he development of an effective vaccine against human immunodeficiency virus (HIV) remains a formidable challenge 30 years after its discovery. Significant advances in the fields of molecular biology, virology, and immunology have led to the development of novel vaccine technologies, including plasmid DNA vaccines, virus-like particle (VLP)-based vaccines, and recombinant viral or other microbial vaccine vectors which have been used to deliver simian immunodeficiency virus (SIV) or HIV immunogens (47) . The most promising design thus far has involved the delivery of SIV or HIV genes by live, recombinant viral vectors with or without priming the immune response with plasmid DNA expressing the desired immunogen (18, 26, 56) . Although there has been significant success in lowering viral loads after challenge with pathogenic SIV or simian-human immunodeficiency virus (SHIV) and long-term control of viremia in rhesus macaques, none of these technologies have induced complete protection against disease much less against infection (11) . For those vaccine modalities showing the most promising immunological results in nonhuman primate models, expanded phase II and phase III human trials testing antibody-based and T cell-based HIV-1 vaccines have failed (29, 36) . More recently, a heterologous prime-boost strategy, combining a canarypox prime (ALVAC) followed by protein boost (VAXGEN), provided modest and transient protection against infection shortly after vaccination; however, the vaccine regimen had no effect on set point viral load after acquisition, and protection against acquisition waned as time after vaccination increased (42) . Therefore, failure to protect against infection and disease in rigorous primate challenge models may correlate with failure to protect against infection and disease in humans.
In nonhuman primate models to date, live attenuated SIV vaccines have offered the highest degree of protection against mucosal and systemic challenge with uncloned, pathogenic SIV isolates (8, 22, 31, 55) . Integration of the proviral DNA into the host chromosome and the persistent nature of lentiviruses, combined with their high rate of mutation and evolution, are safety concerns precluding the continued development of live attenuated HIV for human trials. However, if a safe, live attenuated virus vaccine could be developed, it might have the potential to induce significantly improved protection against HIV-1 infection. Thus, the goal is to design a vaccine which incorporates the advantages of a live attenuated virus vaccine without the inherent safety issues surrounding the use of attenuated lentiviruses.
Alphaviruses from the Togaviridae family of positive-strand RNA viruses are widely used as vectors to express heterologous proteins, both in vitro and in vivo (39, 50) , and have been used as vaccine vectors to deliver SIV and HIV antigens that are immunogenic (1, 3, 4, 10, 34, 35) . The 5= end of the genome encodes four nonstructural proteins which form the replicase complex for transcription and replication of the RNA genome. The alphavirus structural proteins are expressed from a subgenomic RNA transcribed from the 26S subgenomic promoter immediately downstream of the replicase genes. Replacement of the alphavirus structural genes with a gene of interest downstream from the internal 26S subgenomic mRNA promoter results in high levels of heterologous protein expression. A second functional 26S promoter and associated heterologous gene may be inserted downstream from the first heterologous gene cassette, driving the expression of an additional gene insert (9, 40) .
Assembly of lentiviral particles is primarily mediated by the viral protein Gag. In the absence of other viral proteins, Gag proteins multimerize via dimerization domains located in the C terminus of capsid and self-assemble into immature particles that are competent to bud from the cell. Assembly requires RNA, and Gag particles nonspecifically acquire RNA during the assembly process in the absence of lentivirus genomic RNA (2, 14) . Expression of Gag from alphavirus replicon RNA is sufficient for assembly of Gag particles (5) . The lentivirus accessory genes are not required for optimal lentiviral structural gene expression as all of the genes and cis-acting sequences required for alphavirus RNA transcription and replication are contained in the replicon genome, and alphavirus replication is exclusively cytoplasmic with no DNA intermediate. Also, it has been shown that HIV Gag expression from the positive-strand RNA virus Japanese encephalitis virus results in efficient Gag VLP assembly in the absence of the HIV accessory proteins Rev and Rev-responsive element (RRE) (58) .
The design of the chimeric virus vaccine prototype described here utilizes the RNA genome from the alphavirus Venezuelan equine encephalitis virus (VEE) encoding a subset of lentivirus gene products sufficient for self-assembly of lentivirus-like particles that present Gag and Env in their native conformations. If the replicon RNA were packaged into such chimeric particles and if the replicon genome were then released into the cell cytoplasm after entry of the chimeric particles into susceptible cells, then the chimeric particles could potentially self-propagate and function as a live virus vaccine. The vaccine would induce innate immune responses and would be cleared from the body after sufficient induction of adaptive humoral and cellular responses to the lentivirus immunogens. Using this system, the inherent safety limitations of live attenuated lentivirus vaccines may be overcome, based on the following observations. (i) Alphaviruses replicate exclusively in the cytoplasm of the infected cell. There is no DNA intermediate, no nuclear replicative step, and hence no integration into the host chromosome. (ii) Alphaviruses, particularly VEE, are sensitive to interferon, and attenuating mutations to increase interferon sensitivity can be engineered into the genome to limit its replication further (54) . Since there is no integration into the host genome and replication is self-limiting, vaccination should not lead to persistent or chronic infection.
This design, in theory, conserves the best aspects of a live attenuated virus vaccine by presenting the major lentivirus antigens in native form to elicit a broad, balanced immune response while overcoming many of the inherent safety issues associated with attenuated lentiviruses as vaccines. The prototype chimeric virus vaccine candidate developed here contains a VEE-SHIV89.6P chimeric virus genome and SHIV89.6P gag, pro, and env genes, utilizes the SHIV89.6P coreceptors for cell entry, and can be propagated by serial passage in cell culture.
MATERIALS AND METHODS
Cells. Vero E6 cells (ATCC CRL 1586) were maintained in Dulbecco's modified Eagle's medium-F12 (DMEM-F12) containing 10% fetal bovine serum and 1% penicillin and streptomycin and supplemented with 0.29 g/ml of L-glutamine. Baby hamster kidney cells (BHK) cells (ATCC CCL10) were maintained in alpha minimal essential medium (␣-MEM) containing 10% donor calf serum, 10% tryptose phosphate broth, and 1% penicillin and streptomycin, supplemented with 0.29 g/ml L-glutamine. For electroporation, BHK cells were cultured in 10% fetal bovine serum. NIH 3T3 cells (ATCC CRL 1658) and 3T3 cell lines expressing CD4, CCR5, and CXCR4 (NIH AIDS Research and Reference Program [NARRP] 3947 and 3948) were maintained in DMEM containing 10% fetal bovine serum and 1% penicillin and streptomycin, supplemented with 0.29 g/ml of L-glutamine. The NIH 3T3.CD4.CCR5 cell line was also supplemented with 3 g/ml puromycin. U87.CD4.CCR5 and U87.CD4.CXCR4 cells (NARRP 4035 and 4036) were maintained in DMEM containing 15% fetal bovine serum and 1% penicillin and streptomycin, supplemented with 0.29 g/ml of L-glutamine, 1 g/ml of puromycin, and 300 g/ml of G418.
Plasmids expressing VEE replicon RNA and chimeric viral genomes. (i) Construction of VEE replicon plasmids expressing SHIV89.6P Gag, GagPR, and Env(gp160). Recombinant Venezuelan equine encephalitis virus (VEE) replicon plasmids were constructed using standard molecular biology techniques. Coding sequences of Gag (nucleotides 536 to 2068), Gag-Pro (GagPR; nucleotides 536 to 2361), gp160 Env (nucleotides 6339 to 8948), and gp160 Env with a truncated cytoplasmic tail (Env⌬CT; nucleotides 6339 to 8493) were PCR amplified from the SHIV89.6P KB9 molecular clone (GenBank accession numberU89134). The 5= primer contained 26S subgenomic promoter sequences, and the 3= primer contained a stop codon and an AscI site for cloning into VEE replicon plasmid pVR21 by overlap extension PCR (19) . The carboxy terminus of NSP4 and 26S promoter sequences (VEE nucleotides 6197 to 7561) were PCR amplified and used in an overlap extension PCR with the fragment containing the SHIV89.6P structural gene (either gag or env) with the 26S promoter to obtain a PCR fragment that contained the carboxyl terminus of NSP4, the complete VEE 26S subgenomic promoter, the SHIV89.6P structural gene, and an AscI restriction site. This was placed into PCR cloning vector Zero Blunt (Invitrogen) and sequenced. An attenuating mutation in the active site of protease, from alanine at position 28 to serine, was introduced by site-directed mutagenesis. SwaI and AscI were used to remove the 26S subgenomic promoter and SHIV89.6P structural genes, and the fragment was placed into VEE replicon plasmid pVR21 also digested with SwaI and AscI. To construct double-promoter replicon plasmids, pVR21 SHIV89.6P Gag and pVR21 SHIV89.6P Env were digested with SwaI and NotI to isolate the 26S promoter and the associated gene. The 26S-Gag fragment was ligated into pVR21 SHIV89.6P Env digested with PmeI and NotI to create the double-promoter replicon plasmid pVR100 SHIV89.6P Env-Gag. The 26S-Env fragment was ligated into pVR21 SHIV89.6P Gag, GagPR, or GagPR(A28S) digested with PmeI and NotI to create pVR100 SHIV89.6P Gag-Env, GagPR-Env, and GagPR(A28S)-Env. Positive clones were identified by restriction diagnostics and were verified by sequencing.
(ii) Construction of VEE replicon plasmids expressing SHIV89.6P GagPR(A28S)⌬NC؉VEE C sub -Env. The VEE capsid fragment consisting of amino acids 75 to 132 [VEE C(75-132)] was molecularly cloned to replace the nucleocapsid (NC) region of SIV Gag (Gag⌬NCϩVEE C sub ). The VEE C fragment was synthetically produced (Biobasic, Amherst, NY) to include the sequence between EcoNI and AscI incorporating the VEE C(75-132) region within the proteolytic cleavage sites for p22NC (CCTT TTGCAGCA2GCCCAACAG) and NC2p1 (AGACAGGCGGT2TTTTTA GGC) (protease cleavage site denoted by the down arrow). The VEE C fragment was digested with EcoNI and AscI and cloned into pVR21 Gag to produce replicon plasmid pVR21 Gag⌬NCϩVEE C sub . pVR21 GagPR(A28S) was then digested with PpuMI and AscI and ligated into pVR21 Gag⌬NCϩVEE C sub digested with PpuMI and AscI to construct replicon plasmid pVR21 GagPR(A28S)⌬NCϩVEE C sub . Doublepromoter replicon plasmid pVR100 was constructed by digesting pVR21 Env with SwaI and NotI and ligating the fragment into pVR21 GagPR⌬NCϩVEE C sub or pVR21 GagPR(A28S)⌬NCϩVEE C sub cut with PmeI and NotI as described above to create pVR100 GagPR(A28S)⌬NCϩVEE C sub -Env. Positive clones were identified by restriction diagnostics and were verified by sequencing.
RNA transfection. NotI-linearized VEE replicon plasmids encoding SHIV89.6P Gag, Env, Gag-Env, or Env-Gag and their modified derivatives were used as templates for the synthesis of capped VEE replicon RNAs using an mMessage Machine T7 kit (Ambion). Subconfluent Vero or BHK cells were harvested and prepared for electroporation. Cells were pelleted by centrifugation (at 800 ϫ g for 10 min), washed with RNase-free phosphatebuffered saline (PBS; Accugene), and resuspended to 1.5 ϫ 10 7 cells/ml in RNase-free PBS. Fifty micrograms of in vitro synthesized replicon RNA was transfected into Vero or BHK cells by electroporation of 800 l of resuspended cells using five electrical pulses of 450 V (Vero) or three electrical pulses of 850 V (BHK) at 25 F with a Bio-Rad gene pulser II electroporator and 0.4-cm-gap gene pulser cuvettes (Bio-Rad). Transfected BHK cells were placed into 75-cm 2 flasks containing complete medium, and transfected Vero cells were placed into 175-cm 2 flasks containing either complete medium or virus production serum-free medium (VP-SFM; Invitrogen) supplemented with 0.29 g/ml of L-glutamine. Cells were incubated for 24 to 28 h at 37°C in 5% CO 2 .
Production and harvesting of chimeric lentivirus-like particles. Supernatants from Vero cells or BHK cells transfected with SHIV89.6P Gag, Env, Gag-Env, or Env-Gag replicon RNA and their modified derivatives were clarified of cell debris by centrifugation at 12,000 ϫ g for 30 min at 4°C or at 3,000 ϫ g for 15 min at 4°C. Supernatants were filtered through a 0.45-m-pore-size filter and concentrated by ultracentrifugation at 72,000 ϫ g for 4.5 h at 4°C through a 20% sucrose or OptiPrep (Accurate Chemical & Scientific Corporation) cushion. Pellets were resuspended overnight in 250 l to 500 l of PBS at 4°C. Alternatively, particles were concentrated to 1 ml using Amicon Centriplus YM-100 centrifugal concentrators (Millipore) at 3,000 ϫ g at 4°C. Particle production was assessed by determining the p27 content using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Zeptometrix) or by semiquantitative Western blotting. Supernatants from cells transfected with SHIV89.6P Env RNA served as controls for infection mediated by Env microvesicles.
For density gradient analysis, concentrated supernatants were layered onto a 10% to 50% continuous OptiPrep gradient, and the particles were banded by ultracentrifugation at 72,000 ϫ g for 15 h at 4°C. One-milliliter fractions were collected starting from the bottom of the gradient using a peristaltic pump (VWR brand mini-pump; variable flow). The density of each fraction was determined, and the protein content was analyzed by Western blotting, probing with anti-SIVmac251-infected monkey sera (NARRP 2773).
Production of VRP. Preparation of VEE replicon particles (VRP) has been previously described (38) . Briefly, in vitro transcribed replicon RNA expressing SHIV89.6P Gag, SHIV89.6P Env, or a replicon RNA lacking a transgene (null VRP) (49) and two defective helper RNAs expressing VEE capsid and VEE glycoproteins (V3000) were transfected into BHK cells. Particles produced in this way contain the replicon RNA packaged in the VEE capsid and glycoproteins. VRP-containing supernatants were harvested at 24 h postelectroporation, clarified, and concentrated through 20% sucrose as described above. VRP titers were determined by indirect immunofluorescence staining using mouse serum containing antibody against the VEE nonstructural proteins. VRP-expressing Env are designated Env-VRP, VRP-expressing Gag are designated Gag-VRP, and VRP lacking a transgene are designated null-VRP.
Western blot analysis of SHIV89.6P structural genes. Transfected Vero cells harvested at 24 h postelectroporation were lysed in NP-40 lysis buffer (50 mM Tris, pH 7.2, 170 mM NaCl, 15 mM EDTA, 0.2% NP-40, containing a protease inhibitor cocktail of phenylmethylsulfonyl fluoride [PMSF] , pepstatin, leupeptin, aprotinin, and anti-pain). Lysates were clarified of nuclei and debris by centrifugation at 13,000 rpm for 5 min at 4°C. A portion of cell lysate or pelleted supernatant was treated with peptide N-glycosidase F (PNGase F; New England BioLabs). Proteins were denatured for 10 min at 100°C in denaturation buffer. The reaction mixture was adjusted to 1ϫ in G7 buffer and 1% NP-40 upon the addition of PNGase F and incubated for 2 h at 37°C. Treated and untreated cell lysates and concentrated supernatants were separated by 8% or 10% SDS-PAGE and transferred to a polyvinylidene difluoride (PVDF) membrane (BioRad) by semidry blotting. The membrane was blocked overnight in Trisbuffered saline containing 0.1% Tween 20 (TBS-T) and 5% dry milk or ECL Block (Amersham). SHIV89.6P antigens were detected by probing the membrane with either sera from SHIV89.6P-infected monkeys (generously provided by David Montefiore, Duke University, Durham, NC), diluted 1:1,000, or sera from SIVmac251-infected monkeys (NARRP 2773), diluted 1:1,000, followed by horseradish peroxidase (HRP)-linked anti-monkey IgG (Sigma) secondary antibody at a 1:5,000 dilution. SHIV89.6P envelope was detected with either HIV-Ig (NARRP 3957), HIV-1 gp120 monoclonal 2G12 (NARRP 1476), or HIV gp41 monoclonal antibodies 2F5 and 4E10 (NARRP 1475 and 10091) at 1:10,000, followed by HRP-linked anti-human IgG (Vector Labs) secondary antibody at a 1:20,000 dilution. Immunoreactive proteins were detected using an enhanced chemiluminescence system (ECL; Amersham Biosciences).
Immunoprecipitation of chimeric lentivirus-like particles with anti-HIV gp120 IgG1 b12. Concentrated supernatants from cells mock transfected or transfected with SHIV89.6P Gag, Gag-Env, or Env-Gag replicon RNA were incubated with naïve monkey sera and protein A-Sepharose CL-4B beads (Sigma) for 3 h at 4°C with agitation. Beads were pelleted by centrifugation at 15,000 ϫ g for 5 min at 4°C, and the supernatants were transferred to a new tube containing anti-HIV gp120 antibody IgG1 b12 (NARRP 2640) or anti-hemagglutinin (HA) monkey serum as an irrelevant antibody control. After 3 h of incubation at 4°C with agitation, the supernatants were transferred to a new tube containing protein A-Sepharose beads and incubated overnight at 4°C with agitation. Beads were pelleted by centrifugation and washed three times with NP-40 lysis buffer and once with 50 mM Tris-HCl, pH 7.6. Pelleted beads were resuspended in 30 l of 2ϫ SDS Laemmli sample buffer. The immunoprecipitated proteins were separated by 10% SDS-PAGE and transferred to a PVDF membrane (Bio-Rad) by semidry blotting. SHIV89.6P Gag was detected by probing the membrane with anti-Gag monoclonal antibody KK64 (NARRP 2320) diluted 1:1,000, followed by HRP-linked antimouse IgG (Amersham) secondary antibody at a 1:5,000 dilution and detected using ECL (Amersham).
Transmission electron microscopy (TEM). Vero and NIH 3T3.CD4.CCR5 cells grown and treated on standard tissue culture plates were processed in situ. The cell monolayers were rinsed briefly with serum-free medium and fixed with 4% glutaraldehyde in 0.15 M sodium phosphate buffer, pH 7.4, for several hours to overnight. Following three rinses with phosphate buffer, the monolayers were postfixed for 1 h in a mixture of 1% osmium tetroxide and 1.25% potassium ferricyanide in 0.15 M sodium phosphate buffer. The cells were rinsed in deionized water and dehydrated through increasing concentrations of ethanol (30%, 50%, 75%, 100%, and 100%; 5 min each). Cells were infiltrated with two changes of Polybed 812 epoxy resin (1A:2B formulation; Polysciences, Inc., Warrington, PA) for several hours each change. The plates were polymerized overnight (24 h) at 60°C, and the embedding capsules were separated from the plates prior to sectioning. Ultrathin sections (70 nm) were cut using a Diatome diamond knife; sections were mounted on 200-mesh copper grids and stained with 4% aqueous uranyl acetate for 15 min, followed by Reynolds' lead citrate for 7 min. Sections were observed and photographed using a LEO EM910 transmission electron microscope at 80 kV (LEO Electron Microscopy, Thornwood, NY).
Immunoelectron microscopy. Vero cells were grown and treated on Nunc glass chamber slides. 3T3.CD4.CCR5 cells were grown and treated on Nunc 13-mm round Thermanox coverslips. After samples were rinsed with serum-free medium, the cells were fixed with 2% paraformaldehyde-0.5% glutaraldehyde in 0.15 M sodium phosphate, pH 7.4, for several hours. Following glutaraldehyde and paraformaldehyde fixation, the samples were rinsed three times with sodium phosphate buffer followed by 10 min in 30% ethanol, 50% ethanol, and an en bloc stain with 2% uranyl acetate in 50% ethanol for 15 min. The cells were rinsed with 50% ethanol and dehydrated with increasing concentrations of ethanol (75%, 90%, 100%, and 100%). The slides/coverslips were infiltrated overnight in LR white resin (hard grade; Ted Pella, Inc., Redding, CA) at 4°C. Following a change with fresh resin, the chamber slides/coverslips were polymerized at 55°C overnight (24 h).
For the infected NIH 3T3.CD4.CCR5 cells, the cell monolayers containing syncytia were specifically embedded in resin. The embedded cells were separated from the glass slide, and 80-nm ultrathin sections were cut parallel to the substrate using a Diatome diamond knife. The sections were mounted on 300-mesh nickel grids and were stained by floating the grids, section side down, on 20-l droplets of the reagents. All sections were blocked before antibody exposure for 20 min in Aurion Goat Gold Conjugate Blocking Solution (catalog number 25596; Electron Microscopy Sciences, Inc., Fort Washington, PA). The grids were incubated for 90 min at room temperature in a 1:100 dilution of primary mouse anti-Gag monoclonal antibody KK59 (NARRP 2320) and a 1:50 dilution of human anti-HIV gp120 antibody IgG1 b12 (NARRP 2640) in 50 mM Trisbuffered saline with 0.1% cold water fish skin gelatin and 0.01% Tween 20, pH 7.6 (TBSFT). A negative control with normal mouse immunoglobulins was performed concurrently. Following six brief rinses in TBSFT, the sections were incubated for 2 h at room temperature in the secondary antibody, a 1:50 dilution of goat anti-mouse antibody conjugated to 5-nm colloidal gold beads or a 1:50 dilution of biotinylated goat anti-human antibody in TBSFT. Sections were rinsed in TBSFT and incubated with anti-biotin conjugated to 20-nm colloidal gold beads for 2 h. After samples were rinsed with TBSFT, the immunogold-stained grids were contrasted with 4% aqueous uranyl acetate for 10 min. Sections were observed and photographed using an LEO EM910 transmission electron microscope at 80 kV.
Detection of viral RNAs incorporated into chimeric lentivirus-like particles by TaqMan real-time PCR.
Particle preparations produced in Vero cells and concentrated by pelleting through 20% OptiPrep were incubated with 25 U/ml of Benzonase nuclease for 5 min at room temperature. Nuclease was inactivated with 150 mM NaCl, and the particle preparations were serially diluted 10-fold, in duplicate. Encapsidated RNA was extracted using a MagMax Viral RNA Isolation Kit (Ambion) per the manufacturer's instructions and was subsequently treated with RNasefree DNase (2 U of Turbo DNA-free DNase; Ambion).
Viral genomic and subgenomic RNAs were detected by TaqMan realtime PCR. Primer sets and 5= 6-carboxyfluorescein (FAM) reporter dye and 3= 6-carboxytetramethylrhodamine (TAMRA) quencher probes for the detection of sequences in VEE NSP1 (forward primer, 5=-GCCTGTA TGGGAAGCCTTCA; reverse primer, 5=-TCTGTCACTTTGCAGCACA AGAAT; probe, 5=-56-FAM-CCTCGCGGTGCATCGTAGCAGC-36-TAMSp), SIVmac239 Gag (forward primer, 5=-CAAGCGGCTAT GCAGATTATCA; reverse primer, 5=-TGGTTGTGGGTGCTGCAA; probe, 5=-56-FAM-AGATATTATAAACGAGGAGGCTGCAGATTGGG A-36-TAMSp), and SHIV89.6P Env (forward primer, 5=-AGCTGTGTT CCTTGGGTTCTTG; reverse primer, 5=-CTGTACCGTCAGCGTCAC TGA; probe, 5=-56-FAM-CAGCAGGAAGCACTATGGGCGCAG-36-TA MSp) were designed using PCR Express, version 2.0 (Applied Biosystems). RNA transcripts from pVR100 SHIV89.6P Gag-Env were DNase treated, quantitated by spectrophotometry, and diluted 15-fold, in duplicate, to generate a standard curve starting at 9 ϫ 10 6 genome equivalents and ending at a limit of detection of 200 genome equivalents. Five microliters of RNA standard or extracted RNA was added to one-step reverse transcription-PCR (RT-PCR) mixtures containing TaqMan One
Step RT-PCR Master Mix Reagents (Applied Biosystems), 900 nM forward and reverse primer, and 250 nM probe in Microamp optical 96-well reaction plates (Applied Biosystems). RNA was detected using Applied Biosystems real-time PCR using the default thermal cycling conditions for one-step RT-PCR: 48°C for 30 min, 50°C for 2 min, 95°C for 10 min, and 40 cycles of denaturation at 95°C for 15 s followed by annealing and extension at 68°C for 1 min. The data were collected and analyzed using Sequence Detection, version 1.2.3, software (7000 Systems SDS Software RQ study application; Applied Biosystems).
To account for nonspecific background, raw values obtained for control reactions without reverse transcriptase were subtracted from the values obtained in the presence of reverse transcriptase. A replicon RNA standard was measured with each primer-probe set to generate a standard curve for each primer-probe set used to determine the amount of genomic and subgenomic RNA in particle preparations. The number of RNA genomes/ml was determined by averaging values obtained for two or three dilutions of RNA extracted from particles and normalized to the p27 content of the particle preparation. The amount of genomic RNA present in particle preparations was detected using a primer probe set specific for the NSP1 region of the viral genome. To determine the amount of subgenomic RNA from the 5=-most 26S subgenomic promoter (subgenome 1), the amount of genomic RNA (value obtained with the NSP1 primer/ probe set) was subtracted from the value obtained with the Gag primer/ probe set for Gag-Env or the value obtained with the Env primer/probe set for Env-Gag. To determine the amount of subgenomic RNA from the 3=-most 26S subgenomic promoter (subgenome 2), the value for genomic RNA and the amount of subgenomic RNA 1 were subtracted from the value obtained for subgenome 2 (value obtained with the Env primer/ probe set for Gag-Env or the value with the Gag primer/probe set for Env-Gag). The values for genomes, subgenome 1, and subgenome 2 for three independent experiments were averaged, and the standard error of the mean was calculated.
Infection of cell lines with chimeric lentivirus-like particles and Env-VRP. NIH 3T3, 3T3.CD4.CCR5, and 3T3.CD4.CXCR4 cells were mock infected, infected with undiluted Gag-Env or Env-Gag chimeric particles, or infected with Env-VRP at a multiplicity of infection (MOI) of 0.1. Eighteen hours postinfection, the cells were rinsed with PBS and fixed with 2% paraformaldehyde. Gene expression was detected by indirect immunofluorescence. Infected cells were rehydrated with diluent (1ϫ PBS, 1% donor calf serum [DCS], Ca 2ϩ , Mg 2ϩ , 0.1% normal horse serum, and 0.1% saponin) and blocked with diluent containing 5% normal horse serum. The cells were incubated for 1 h at room temperature with either (i) sera from mice infected with null-VRP plus ovalbumin (OVA) to detect VEE nonstructural protein expression, (ii) sera from mice infected with Gag-VRP to detect Gag expression, or (iii) anti-gp120 antibody b12 to detect Env expression. The cells were then washed three times with diluent. Cells were incubated with biotinylated anti-mouse IgG or with biotinylated anti-human IgG for 1 h, washed three times with diluent, incubated with Alexa Fluor 594-streptavidin conjugate (Invitrogen) for 30 min, and washed three times with diluent. Cells containing VEE nonstructural proteins and SHIV89.6P structural proteins were visualized by fluorescence microscopy and photographed.
Titration of chimeric lentivirus-like particle preparations. NIH 3T3.CD4.CCR5/CXCR4 or U87.CD4.CCR5/CXCR4 cell monolayers in 48-well dishes were infected with 2-fold dilutions of filtered, unconcentrated supernatants containing chimeric particles or supernatants containing Env microvesicles produced in cells transfected with Envexpressing replicon RNA in the absence of Gag. At 24 h postinfection, cell monolayers were fixed with methanol and acetone. Syncytia were detected by immunostaining with HIV-IG (NARRP 3957) and visualized using a Vectastain ABC kit and VIP substrate (Vector Laboratories). Syncytia were enumerated as plaques, and titers were determined as in a standard plaque assay. Alternatively, U87.CD4.CXCR4 cells in eight-well glass slides were either mock infected, infected with Env-VRP, treated with undiluted Env microvesicle preparation (Env MV), or infected with 10-fold serial dilutions of concentrated chimeric lentivirus-like particle preparations. At 10 to 12 h postinfection, cells were fixed in methanol for 5 min and air dried. The cells were permeabilized in 1ϫ TBS, 3% bovine serum albumin (BSA), 0.1% Triton X-100, and 1% normal goat serum and blocked with 1ϫ PBS, 5% BSA, and 5% normal goat serum. Cells were then stained with sera from mice infected with null-VRP plus OVA, and positive syncytia were detected by indirect immunofluorescence and enumerated as described above.
For 50% tissue culture infective dose (TCID 50 ) determination, U87.CD4.CXCR4 cells were infected with 2-fold serial dilutions of particle preparations. The cells were fixed in methanol, and syncytia were detected by indirect immunofluorescence as described above. Cytopathic effect (CPE) was scored by syncytium formation, and the TCID 50 value was determined by the method of Reed and Muench (41) .
Serial passage and propagation of chimeric lentivirus-like particles. NIH 3T3.CD4.CCR5 cells were infected with 1 ϫ 10 2 IU of chimeric particles for 1 h at 37°C with 5% CO 2 . After infection, inoculum was removed, cells were washed three times with 1ϫ PBS, fresh medium was added, and cells were incubated for 48 h at 37°C in 5% CO 2 . At 48 h postinfection, the viral supernatants were clarified by centrifugation at 3,000 rpm for 15 min, followed by filtration through a 0.22-m-pore-size filter. Viral titers were determined on NIH 3T3.CD4.CCR5 cells as described above. A fraction of the viral supernatant was used as the inoculum for the next passage. The dilution of the viral supernatants was modified based on the number of syncytia seen at the conclusion of each viral passage: a 1:10 dilution was used for infection of passages 2 and 3, and a 1:100 dilution was used for infection of passage 4 and passage 5 to maintain passages at low MOIs.
To measure the growth rate of chimeric lentivirus-like particles, NIH 3T3.CD4.CCR5 cells were infected with 1 ϫ 10 2 IU of chimeric particles for 1 h at 37°C in 5% CO 2 . After 1 h, the inoculum was removed, cells were washed three times with 1ϫ PBS, and fresh medium was added to each flask. Samples were taken at 12-h intervals for 72 h starting immediately after infection (0 h postinfection [hpi]), and the titer of progeny virions was determined on NIH 3T3.CD4.CCR5 cells as described above.
RESULTS
We hypothesized that if the HIV structural genes gag and env were expressed from VEE replicon RNA, they would self-assemble into immature particles that presented both Gag and Env in their native conformations. If the chimeric viral RNA was packaged into the particles and if that genome was then released after entry of the particles into susceptible cells, then the particles containing chimeric viral RNA could potentially self-propagate and function as an attenuated virus vaccine (Fig. 1) . To determine if such a chimeric lentivirus-like particle could be created as a potential live attenuated virus vaccine candidate, a prototype VEE-SHIV89.6P chimeric virus was created.
Expression of SHIV89.6P structural genes gag and env from VEE RNA. An established reverse genetics system to modify VEE replicon RNA was used to express the SHIV89.6P structural genes gag and env in place of the VEE structural genes, thus creating chimeric VEE-SHIV viral genomes (Fig. 1A) . Two versions of the virus genome were constructed, differing in the position of gag and env cassettes since expression from the 3=-most 26S promoter is higher than expression from the 5=-most 26S promoter (9, 40) . After transfection of genomic RNA into Vero cells, Gag and Env were expressed to high levels, and particles were assembled and released into the cell culture supernatant ( Fig. 1B and 2A ; see Fig. S1B in the supplemental material). In the cell lysates, Env appeared as a doublet corresponding to gp160 and gp120. A band corresponding to gp41 was also present ( Fig. 2A; see Fig. S1 and S2). After treatment with the amidase N-glycosidase F (PNGase F), bands corresponding to the size of deglycosylated gp160, gp120, and gp41 appeared, supporting the conclusion that the bands migrating at 160, 120, and 40 kDa are Env and that gp160 is cleaved into gp120 and gp41 although cleavage was not complete ( Fig. 2A; see Fig. S2 and S3). Env was not usually detected in the concentrated supernatants by Western blotting except in a few particle preparations, although a very faint band corresponding in size to gp120 was detected in concentrated supernatants upon overexposure of the membrane ( Fig.  2A; see Fig. S1 ). This is consistent with low incorporation of Env into lentivirus virions (7, 59) .
Gag expression was higher from Env-Gag RNA than from GagEnv RNA, and Env expression was higher from Gag-Env RNA than from Env-Gag RNA, consistent with published observations regarding gene placement in alphavirus double-promoter RNAs (40) . These observations were confirmed by measuring the amount of Gag present in Gag-Env and Env-Gag particle preparations by p27 ELISA (data not shown). Gag and Env expressed to similar levels and assembled and released similar amounts of lentivirus-like particles from Vero and BHK cells. Gag and Env were also expressed and assembled and released from 3T3 (murine) cells although particle production was slightly reduced (see Fig. S1 in the supplemental material). Partially purified particles produced in Vero cells sedimented at a density of 1.13 to 1.18 g/ml in continuous OptiPrep gradients, similar to lentivirus particles in density and heterogeneity (Fig. 2B) . Peak fractions were pooled and assessed for infectivity as described below. These results suggest that lentivirus-like particles are assembled and released after expression of Gag and Env from double-promoter VEE replicon RNA in rodent and primate cells.
Since Env was not usually detected in partially purified supernatants from Vero cells transfected with Gag-Env or Env-Gag RNA by Western blotting, Env incorporation was assessed by immunoprecipitating partially purified particle preparations with an antibody against gp120 and detecting Gag by Western blotting. As negative controls, Gag VLPs produced from VEE replicon RNA expressing Gag in the absence of Env were used, and an irrelevant antibody directed against influenza virus hemagglutinin (HA) also was included. Antibodies against Env gp120 specifically immunoprecipitated particles that contained both Gag and Env (Fig.  2C, lanes 6 and 8) , but particles were not immunoprecipitated with the negative-control antibody directed against influenza virus HA (lanes 5 and 7). Gag VLPs, which did not contain Env, were not immunoprecipitated by either anti-gp120 or anti-HA (lanes 3 and 4). These results suggest that Env was present on the particles but at a level insufficient to be readily detected by Western blotting. Since Env is expressed to higher levels from Gag-Env RNA than from Env-Gag RNA, more particles containing Env spikes may be present in virus preparations from cells expressing GagEnv than Env-Gag, and this may be reflected in the increased amount of Gag detected in the Gag-Env particle preparation (lane 6 compared to lane 8).
To improve the incorporation of Env into chimeric lentiviruslike particles, the cytoplasmic tail was truncated at amino acid 718, two amino acids after the transmembrane domain of gp41. The molecular masses of gp120 and gp41 after truncation of the cytoplasmic tail were expected to be approximately 105 and 25 kDa, respectively. Chimeric lentivirus-like particles were produced and partially purified as described in Materials and Methods, and the incorporation of Env into the particles was determined by Western blotting using monoclonal antibodies 2F5 and 4E10. As previously observed in Fig. 1 , Env was not detected in Gag-Env or Env-Gag particle preparations. Env was readily detected in GagEnv⌬CT or Env⌬CT-Gag particle preparations by Western blotting, suggesting that the truncation significantly improved incor- poration of Env into Gag-Env⌬CT or Env⌬CT-Gag particles (see Fig. S2 in the supplemental material) .
Morphogenesis of chimeric lentivirus-like particles in Vero cells expressing Gag and Env. To assess the morphology of the particles produced in Vero cells after expression of SHIV89.6P gag and env from VEE RNA, ultrathin sections of transfected cells were visualized by transmission electron microscopy. Mocktransfected cells were included as a negative control, and cells transfected with replicon RNA expressing Env served as a control for the formation of Env microvesicles (Env MV) (25) . Mocktransfected cells were normal in morphology, with intact organelles (Fig. 3A) . Cells transfected with Env replicon RNA accumulated significantly more mitochondria, and these appeared to be deteriorating (data not shown). Significant accumulation of smooth membrane vesicles was observed in Env-expressing cells compared to cells that were mock transfected, and more vesicles appeared to be released from the Env-expressing cells (compare Fig. 3A and B) . In contrast, cells transfected with VEE RNA expressing Gag alone accumulated large intracellular vacuoles that periodically contained Gag VLPs (data not shown). However, the majority of Gag VLPs produced were released from the plasma membrane into the extracellular space (data not shown).
Vero cells transfected with Gag-Env and Env-Gag RNAs produced particles with the size and morphology of immature lentivirus particles. These were found primarily in the extracellular space ( Fig. 3C and D) . The sizes of the particles ranged between 105 nm and 158 nm, with an average of 133.8 Ϯ 12.8 nm. Particles budding from the plasma membrane into the extracellular space suggested that assembly and budding of the particles occurred at the plasma membrane in Vero cells. Some intracellular accumulation of particles in vacuoles was observed in Vero cells transfected with Env-Gag RNA; however, the majority of the particles were released from the plasma membrane, as was observed for expression of Gag alone. Some accumulation of intracellular vesicles also was observed in cells transfected with Gag-Env and EnvGag RNA; however, it was not to the extent observed in Env RNAtransfected cells. More particles appeared to be produced in cells transfected with Env-Gag RNA than with Gag-Env RNA, consistent with a higher level of expression of Gag from the Env-Gag construct than from the Gag-Env construct.
To verify that the particles produced in the Vero cells were SHIV89.6P lentivirus particles containing both Gag and Env, ultrathin sections were double immunogold labeled with SIV Gag p17 matrix (MA) monoclonal antibody visualized with a small 5-nm gold-labeled secondary antibody and labeled with HIV gp120 b12 monoclonal antibody, followed by biotinylated secondary antibody and antibiotin conjugated to a large 20-nm colloidal gold bead (Fig. 3E to H) . Minimal nonspecific background was observed after mock-transfected cells were stained with the primary and gold-conjugated secondary antibodies (Fig. 3E) . Env was detected in the cytoplasm, often near mitochondria and intracellular vacuoles in cells transfected with replicon RNA expressing Env alone (Fig. 3F) . Vero cells expressing Gag and Env from VEE replicon RNA contained significant amounts of labeled Magnifications, ϫ10,000 (A), ϫ20,000 (B, C, D, and F), ϫ25,000 (E), and ϫ63,000 (G and H).
Env that was not associated with particles (data not shown). Given the fixation procedures inherent in immunogold labeling, it was not possible to unequivocally observe whether Env in the cytoplasm was associated with intracellular membranes. Gag also was detected in the cell cytoplasm, although not as readily detected as Env (data not shown).
The lentivirus-like particles produced in Vero cells contained both SIV Gag and HIV Env, demonstrating that both Gag and Env are incorporated into the chimeric lentivirus-like particles. Similar amounts of Env appeared to be incorporated into particles produced from Gag-Env and Env-Gag RNAs, suggesting that the decreased expression of Env from Env-Gag RNA does not have an effect on Env incorporation into particles ( Fig. 3G and H) .
Chimeric lentivirus-like particles nonspecifically incorporate VEE genomic and subgenomic RNA. In the absence of genomic RNA, Gag utilizes cellular RNA to assemble particles (17, 43, 48) . In addition, Semliki Forest virus replicon RNA is packaged into retrovirus particles (28, 37) . As alphaviruses inhibit host transcription during replication, viral RNAs are the most abundant intracellular RNAs, other than rRNA, during an alphavirus infection. Hence, assembled Gag particles may nonspecifically incorporate viral RNA. In addition to genomic RNA, two subgenomic RNAs are produced from double-promoter VEE genomes (Fig. 4A) . To assess the viral RNA content incorporated into the chimeric lentivirus-like particles, a quantitative real-time PCR assay was used to differentially detect genomic and subgenomic viral RNAs. Genomic RNA accounted for approximately 10% of the total viral RNA packaged into chimeric particles, while subgenomic RNAs were the most abundant viral RNA species (Fig. 4B) . Surprisingly, the subgenomic RNA content of particle preparations from Gag-Env RNA transfections was different from the RNA content from Env-Gag RNA transfections. Particle preparations produced from Gag-Env RNA incorporated significantly more subgenome 2 (Env subgenome; 77% of total viral RNA) than subgenome 1 (Gag-Env subgenome; 11% of total viral RNA). In contrast, virus particles produced from Env-Gag did not incorporate subgenome 2 (Gag subgenome), and over 85% of total viral RNA was subgenome 1 (Env-Gag subgenome) (Fig. 3) . These results demonstrate that Gag nonspecifically incorporates viral RNA during assembly into particles and that genomic replicon RNA was packaged, albeit to relatively low levels.
Immature lentivirus-like chimeric particles infect cell lines expressing human CD4 and coreceptors CCR5 and CXCR4. NIH 3T3 cell lines that express human CD4 and CCR5 (NIH 3T3.CD4.CCR5) or that express CD4 and CXCR4 (NIH 3T3.CD4.CXCR4) were used to determine if the chimeric lentiviruslike particles were infectious (Fig. 5) . In addition, NIH 3T3 cells that do not express CD4, CCR5, or CXCR4 were included as the parental receptor negative cell line control. After infection of CD4 ϩ CCR5 ϩ (CXCR4 ϩ )-expressing cells with SIV or HIV, Env is expressed at the plasma membrane and catalyzes fusion with neighboring cells by engaging CD4 and CCR5 (CXCR4) receptors to form syncytia. NIH 3T3.CD4.CCR5 cells (Fig. 5A) and NIH 3T3.CD4.CXCR4 cells (data not shown) infected with Env-VRP or with Gag/Env chimeric lentivirus-like particles formed syncytia. VEE nonstructural (replicase) proteins and SHIV structural proteins were consistently detected in the syncytia by indirect immunofluorescence assay (IFA). On occasion, viral structural and nonstructural proteins were de-
FIG 4 Chimeric particles contain VEE genomic and subgenomic RNA. (A) Schematics of the VEE-SHIV chimeric virus genomes and subgenomic RNAs
transcribed from genomic RNA. (B) Chimeric particles incorporate viral RNA. Encapsidated RNA was extracted from nuclease-treated particle preparations, and the percentages of genomic and subgenomic viral RNA incorporated into chimeric lentivirus-like particles were determined by real-time PCR as described in Materials and Methods. The results from three independent experiments were averaged, and the error bars indicate standard errors of the means. Subgenomic RNA containing env was the most abundant viral RNA incorporated into the particles, whereas approximately 10% of the total viral RNA was genomic. NSP, nonstructural protein.
tected in a few individual cells surrounding the syncytia. Rare syncytia were detected in NIH 3T3.CD4.CCR5 cells infected with Env microvesicles (MV) that were positive for VEE nonstructural antigens, but these were significantly fewer than in cultures infected with Env-VRP or chimeric lentivirus-like particles (Fig. 6 and data not shown) . In the parental cell line that lacks the appropriate receptors for infection by SIV or HIV, NIH 3T3 cells, syncytia were not observed after infection with the chimeric lentivirus-like particles, and the monolayers were indistinguishable from mock-infected cells (Fig. 5B) . Although syncytium formation was not observed in NIH 3T3 cells, VEE nonstructural protein expression was detected in cells infected with Env-VRP, which infect using cellular receptors specific for VEE. This confirms that 3T3 cells are capable of supporting VEE genomic RNA replication. These results demonstrate that the immature lentiviruslike chimeric particles were capable of infecting cells expressing human CD4 and CCR5/CXCR4 in a receptor-dependent manner and were capable of directing RNA replication. In addition, Env expressed from VEE RNA was functional, as shown by the formation of syncytia only when the target cells displayed CD4 and CCR5 or CXCR4. Chimeric lentivirus-like particles were also able to infect T cell lines SupT1 and CEMX174 (see Fig. S4 in the supplemental material) and monocyte cell lines THP-1 and U937 (data not shown).
A plaque assay to titrate chimeric virus infectivity was developed based on syncytium formation (30, 45) . Syncytia were enumerated as plaques, and titers were determined as in a standard plaque assay (Fig. 6B) . To validate this methodology of titration, the titer of Env-VRP using a standardized indirect immunofluorescence assay on BHK cells (38) was directly compared to the titer determined by syncytium formation on NIH 3T3.CD4.CCR5 cells and on U87.CD4.CXCR4 cells (Fig. 6A) . The titer of Env-VRP on BHK cells averaged to 1.01 ϫ 10 8 Ϯ 2.99 ϫ 10 7 IU/ml and was similar to the titer determined by syncytium formation on NIH (Table 1) . A representative assay is shown in Fig. 6B . To control for the detection of infectivity mediated by microvesicles that are produced when Env is expressed in cells, we transfected Vero cells with VEE replicon RNA expressing SHIV89.66P Env and purified the microvesicles using the same procedures as described in Materials and Methods for VRP and chimeric particles. Sporadic appearance of syncytia did occur; however, the quantitative titer was below the limit of detection of the assay (Fig. 6B) . Therefore, Env microvesicles do not contribute to the overall titer of chimeric lentivirus particle preparations. The titers of virus preparations produced from Gag-Env and GagEnv⌬CT were also similar. Although the Env cytoplasmic tail truncation increased incorporation of Env into chimeric particles, a significant increase in viral titer was not observed.
Infection of cell lines with the chimeric particles is productive. To confirm that progeny chimeric lentivirus-like particles were assembled after infection of NIH 3T3.CD4.CCR5 cells with chimeric viruses, the syncytia that formed after infection and the extracellular space around syncytia were visualized by TEM. NIH 3T3.CD4.CCR5 cells were mock infected, infected with Env-VRP as a control for Env microvesicles that form from expression of Env, or infected with chimeric lentivirus-like particles. The syncytia that formed after infection were embedded and cut into ultrathin sections for TEM as described in Materials and Methods (Fig.  7A to C) . In addition, sections were double immunogold labeled as described in the legend of Fig. 3 and in Materials and Methods to verify that both Gag and Env were incorporated into progeny particles produced after infection with the chimeric lentivirus-like particles (Fig. 7D to H) . Mock-infected cells were normal in morphology, did not contain large vacuoles, and displayed minimal background staining with antibody-colloidal gold bead complexes (Fig. 7D and data not shown) . In contrast to the Vero cells that were transfected with chimeric virus genomic RNA (Fig. 3) , NIH 3T3.CD4.CCR5 cells infected with Env-VRP or with chimeric lentiviral particles accumulated large perinuclear vacuoles (Fig.  7A to C) . Vacuoles that formed in the Env-VRP-infected cells were either empty (data not shown) or contained some debris (Fig. 7A) . Vacuoles containing microvesicles were also observed (data not shown). Vacuoles that formed in the chimeric lentivirus-like particle-infected cells contained immature lentivirus-like particles that were labeled with SIV Gag and HIV Env gold-conjugated antibodies (Fig. 7B, C, and F to H) . More particles were present in the vacuoles of cells that were infected with Env-Gag chimeric particles than in the vacuoles of cells that were infected with GagEnv chimeric particles (Fig. 7 , compare C to B and F to H). Chimeric lentivirus-like particles were also observed in the extracellular space in cells infected with Gag-Env-derived particles but not in the cells infected with Env-Gag-derived virus ( Fig. 7B and H) .
These experiments demonstrate that chimeric lentivirus-like particles were able to infect susceptible cells, replicate the chimeric viral genomic RNA, and express Gag and Env, leading to the assembly and release of a second generation of progeny chimeric particles. However, further passage resulted in the loss of detectable chimeric particle infectivity.
Modifications to the chimeric VEE-SHIV virus genomes for improved propagation of chimeric lentivirus-like particle vaccines. In the chimeric lentivirus-like particle preparations, large numbers of physical particles appeared to be produced from Vero cells, yet the specific infectivities of these preparations were low when assessed in murine and human cell lines expressing CD4 and CCR5/CXCR4 coreceptors. We hypothesized that the immature form of Gag particles may not efficiently uncoat and release the chimeric particle genome after infection of susceptible cells. In addition, since only 10% of total RNA in particle preparations was genomic, the specificity of genome packaging into the chimeric particles may be too low to sustain propagation. Therefore, a modified SIV protease was added to the chimeric particle genome, and, in parallel, the gag gene was modified to specifically incorporate the chimeric virus genome into the virus vaccine particles.
Maturation of chimeric lentivirus-like particles. Proteasedependent, lentiviral particle maturation occurs either during or after budding from the cell membrane and is required for lentivirus particles to become infectious (24) . Protease (PR) is encoded in the pol open reading frame immediately downstream from gag and is expressed as polyprotein Gag-Pol following ribosomal frameshifting. Ribosomal frameshifting occurs approximately 5 to 10% of the time, and the ratio of Gag to Gag-Pol is approximately 20:1 in lentivirus-infected cells (21) . The ratio of Gag to Gag-Pol precursor proteins in the assembling virion is reflective of the levels of proteins expressed in the cell (46) . Proteolytic processing of Gag and Gag-Pol precursors is tightly regulated and initiates after immature particles have assembled. Overexpression of Gag-Pol in several vector expression systems results in premature protease activation and cleavage of p55 Gag and p160 GagPol, which prevents assembly and release of particles (23, 32) . Mutation of HIV-1 protease at codon 28 in the active-site triad from an alanine to serine (A28S) reduced proteolytic activity by approximately 50-fold without significant effects on substrate binding (20) .
To improve the infectious titer of the chimeric lentivirus-like particles, chimeric viral genomes that incorporate the SIV protease for cleavage of Gag and particle maturation were constructed. The natural frameshift site in SHIV89.6P was maintained, and protease was expressed from the Ϫ1 reading frame relative to the Gag open reading frame. Ten N-terminal amino acids from reverse transcriptase (RT) were added to the C terminus of GagPR to maintain the protease cleavage site and for regulation of the polyprotein processing cascade. Complete intracellular processing of Gag was observed after expression of SHIV89.6P GagPR from VEE replicon RNA in Vero cells, abrogating the formation of particles. Micromolar concentrations of the protease inhibitor saquinavir rescued the assembly and release of Gag particles into the supernatants. Western blot analysis indicated that the particles released in the presence of saquinavir contained the processed forms of Gag (data not shown). Therefore, the attenuating mutation of codon 28 from alanine to serine was introduced into VEE plasmids encoding SIV GagPR-Env. Viral RNA was transfected into Vero cells, and gene expression was analyzed by Western blotting. Gag was extensively processed intracellularly after expression of wild-type GagPR-Env, and significantly fewer particles were assembled or released into the cell culture supernatant (Fig. 8, lane 2) . However, the protease mutation A28S attenuated proteolytic cleavage of Gag intracellularly, and particles containing processed forms of Gag were found in the culture supernatant. The identity of the processed forms of Gag was confirmed by Western blotting, probing with monoclonal antibodies to p17 matrix and p27 capsid (Fig. 8) . In contrast to the concentrated supernatants from transfection with Gag-Env RNA ( Fig. 2  and 8, lane 1) , the presence of Env was detected very well in the concentrated supernatants when it was expressed from GagPREnv (Fig. 8, lane 2) . To assess the morphology of the particles produced from Gag and a truncated Pol protein containing the A28S mutation, ultrathin sections of transfected cells were visualized by transmission electron microscopy. Truncation of Pol did not result in defects in virion assembly, and the particles produced retained the morphology lentiviruses (see Fig. S5 in the supplemental material).
The infectivity of Gag-Env, GagPR-Env, and GagPR(A28S)-Env chimeric particle preparations was quantified by plaque assay, and the Gag content within virus preparations was measured by ELISA to determine if the inclusion of protease improved the specific infectivity of chimeric virus vaccine candidates. Although the viral titers and Gag content varied from experiment to experiment, the results of multiple experiments demonstrated that the inclusion of protease improved the overall infectivity of chimeric virus vaccines, with titers ranging from 1 to 2 logs higher than for Gag-Env chimeric virus. GagPR(A28S)-Env consistently reached higher titers than GagPR-Env and Gag-Env virus and ranged from 1 ϫ 10 4 to 1 ϫ 10 5 (Table 1) . Since the p27 ELISA used in these experiments specifically recognized highly processed forms of Gag, we were unable to accurately determine the specific infectivity of the virus preparations due to the different extents of Gag processing inherent in the different chimeric virus vaccine constructs.
To determine if the addition of protease and particle maturation improved the ability of chimeric virus vaccine particles to propagate, particles produced from Gag-Env, GagPR-Env, and the mutant GagPR(A28S)-Env genomes were passaged on NIH 3T3.CD4.CCR5 cells. Twenty-four hours after infection of NIH 3T3.CD4.CCR5 cells with chimeric virus particles Gag-Env, GagPR-Env, and the mutant GagPR(A28S)-Env, syncytia developed in the cultures. Supernatants from the initial infection were CD4.CCR5 cells infected with chimeric lentivirus-like particles also accumulated large vacuoles that contained progeny chimeric particles that were positive for SIV Gag and HIV Env (B, C, F, G, and H). Occasionally, Gag-Env chimeric particles were released into the extracellular space (B and H). Magnifications, ϫ20,000 (A to C, E), ϫ25,000 (D), and ϫ40,000 (F to H).
harvested and passaged onto fresh NIH 3T3.CD4.CCR5 cell monolayers at a 1:10 dilution as described in Materials and Methods. As observed before, supernatants from Gag-Env particle infection were not capable of a second round of propagation. However, cultures that were infected with GagPR-Env and GagPR(A28S)-Env viruses had detectable syncytia within 24 h, suggesting an improvement in the ability of these chimeric particles to propagate. The supernatants from the second passage were harvested and used to infect fresh monolayers of NIH 3T3.CD4.CCR5 cells at a 1:10 dilution. No syncytia were readily observed in the passage 3 cultures. Therefore, inclusion of the modified SIV protease improved the ability of the chimeric virus particles to propagate in cell culture but was insufficient to sustain long-term propagation.
Incorporation of a putative VEE genomic RNA binding domain into the chimeric virus vaccine particles. In the absence of specific viral genomic RNA encapsidation signals, subgenomic RNA accounted for the majority of the viral RNA incorporated into particles (Fig. 4) . In an alphavirus-infected cell, subgenomic RNA is produced in molar excess over genomic RNA. Specific genomic RNA encapsidation signals have been identified in the NSP1 and NSP2 regions of related alphaviruses, Sindbis virus (52) and Ross River Virus (13) , that are recognized by an RNA binding domain in the capsid protein (15) . The VEE capsid fragment, amino acids 75 to 132, by analogy with Sindbis virus, may bind specifically to the VEE genomic RNA in an unidentified replicase region (51) .
The NC domain of Gag was replaced with a fragment of the VEE capsid (VEE C) protein analogous to that of the Sindbis virus capsid fragment RNA binding domain, while maintaining SIV protease cleavage sites between p22VEE C and VEE C2p2. The modified chimeric virus genome, Gag⌬NCϩVEE C sub -Env, was transfected into Vero cells, and gene expression was analyzed by Western blotting (Fig. 8A, lane 4) . Replacement of the NC domain of Gag with the VEE C domain decreased the overall yield of chimeric lentiviral physical particle production (Fig. 8B, lane 4) ; however, the titer of infectious particles increased by 1 log compared to Gag-Env and ranged from 1 ϫ 10 4 to 1 ϫ 10 5 ( Table 1) . The ability of Gag⌬NCϩVEE C sub -Env to propagate was evaluated by serial passage in NIH 3T3.CD4.CCR5 cells as described above and in Materials and Methods. Although the viral titers improved, after two rounds of serial passage, Gag⌬NCϩVEE C sub -Env also lost the ability to propagate.
To determine if the inclusion of protease and the inclusion of a putative VEE RNA binding domain together could enhance the ability of chimeric lentivirus-like virus particles to propagate, the VEE capsid substitution was placed into the GagPR(A28S)-Env genome to create GagPR(A28S)⌬NCϩVEE C sub -Env. Viral RNA was transfected into Vero cells, and gene expression and particle production were analyzed by Western blotting (Fig. 8, lane 5) . Protease properly cleaved GagPR(A28S)⌬NCϩVEE C sub -Env, indicating that the replacement of the NC domain of Gag with the VEE C binding domain did not result in defective or aberrant cleavage (Fig. 8, compare lane 3 to lane 5) . Also, the inclusion of PR appeared to facilitate assembly and release of chimeric GagPR⌬NCϩVEE C sub -Env particles, as evidenced by the significantly increased amount of unprocessed p56 Gag, p27 capsid, and other processed forms of Gag in the concentrated supernatants after expression of GagPR⌬NCϩVEE C sub -Env genomes (Fig. 8B , lane 5) compared to the amount of unprocessed Gag in the concentrated supernatants from Gag⌬NCϩVEE C sub -Env (Fig. 8B,  lane 4) .
The growth rate of Gag⌬NCϩVEE C sub -Env was compared to that of GagPR(A28S)⌬NCϩVEE C sub -Env to determine if the inclusion of SIV protease improved replication of Gag⌬NCϩVEE C sub -Env. NIH 3T3.CD4.CCR5 cells were infected with 100 infectious units (IU) of Gag⌬NCϩVEE C sub -Env and GagPR(A28S) ⌬NCϩVEE C sub -Env chimeric lentivirus-like particles, and viral growth was measured over time as described in Materials and Methods. Replication of Gag⌬NCϩVEE C sub -Env was detected at 12 hpi and remained steady out to 72 hpi. In contrast, replication of GagPR(A28S)⌬NCϩVEE C sub -Env steadily increased through 60 hpi, suggesting that the two modifications together increased the replication capacity of chimeric lentivirus-like particles (Fig. 9A) .
The ability of GagPR(A28S)⌬NCϩVEE C sub -Env to propagate was evaluated by serial passage on NIH 3T3.CD4.CCR5 cells as described above. GagPR(A28S)⌬NCϩVEE C sub -Env continued to propagate after five serial passages in NIH 3T3.CD4.CCR5 cells. At 48 h postinfection of passage 3, viral CPE measured by syncytium formation was increased compared to the amount of passage 2. Subsequent passages also showed increasing amounts of syncytium formation at 48 h postinfection. To determine if serial passage in NIH 3T3.CD4.CCR5 resulted in increased replication of GagPR(A28S)⌬NCϩVEE C sub -Env, as suggested by increasing levels of CPE after sequential passages, the growth rate of virus harvested after passage 1 was directly compared to the growth rate of virus harvested at passage 5. NIH 3T3.CD4.CCR5 cells were infected with 100 IU of GagPR(A28S)⌬NCϩVEE C sub -Env passage 1 virus and GagPR(A28S)⌬NCϩVEE C sub -Env passage 5 virus, and viral replication was measured over time as described in Materials and Methods (Fig. 9B) . Replication of passage 1 virus continued to steadily rise through 60 hpi, as shown in Fig. 9A . However, viral replication of passage 5 virus continued to rise through 72 hpi and had a 1-log higher titer than passage 1 virus, suggesting that serial passage selected for increasingly fit viruses. The addition of SIV protease and a putative VEE RNA binding domain together was required for sustained propagation of VEE-SHIV chimeric virus vaccine particles.
DISCUSSION
This report describes the development of a novel chimeric live attenuated virus vaccine candidate combining genome elements from distinctly different virus families. Lentiviral structural proteins expressed from chimeric alphavirus genomes self-assembled into lentivirus-like particles that incorporated sufficient amounts functional Env trimers for infectivity and contained the chimeric genomic RNA. Infection of susceptible cells with the chimeric particles was productive, resulting in the uncoating of chimeric viral genomic RNA in the cell cytoplasm, RNA replication, expression of VEE replicase proteins and lentivirus structural proteins, and the assembly and release of propagation-competent progeny chimeric virus particles. The chimeric virus vaccine prototype described here differs from chimeric live attenuated virus vaccines that express heterologous structural proteins from an additional gene cassette placed into the virus genome, and it differs from chimeric live attenuated virus vaccines that express heterologous proteins from a related virus in the same virus family, such as chimeric flavivirus vaccines.
Although recombinant viral vectors expressing SIV/HIV immunogens induce immune responses that result in reduction of viral loads following challenge, consistent and strong protection against infection has yet to be achieved. Only live attenuated versions of SIV have shown protection in rigorous macaque challenge models, but these are considered unsafe for progression to human clinical trials. The chimeric virus approach is designed to mimic a live attenuated lentivirus vaccine for the induction of a robust, balanced immune response that is safe and protective and to have the potential to overcome several limitations of live attenuated lentivirus vaccines: (i) replication is self-limiting due to interferon sensitivity, (ii) RNA replication occurs in the cell cytoplasm and infection is nonpersistent, (iii) viral replication is attenuated due to the addition of the second subgenomic promoter, and (iv) propagation is attenuated due to the chimeric nature of the virus genome.
Self-replicating SHIV89.6P particles derived from chimeric VEE-SHIV genomes were produced after RNA transfection of rodent (BHK), murine (3T3), and primate (Vero) cells. Defects in SIV assembly and release were not observed in BHK and 3T3 cells when results were directly compared to particle production in Vero cells although particle production was somewhat reduced in 3T3 cells. Efficient assembly and release from rodent or murine cells may be due to higher levels of Gag expression from VEE RNA which overcome potential blocks to lentivirus assembly and release. In addition, exchanging SIV MA for HIV MA enhances assembly of HIV in murine cells, suggesting that SIV Gag may not be as restricted for assembly in murine cells compared to HIV Gag (6) . The lower yields of chimeric particles released from 3T3 cells may also be due to assembly and budding into intracellular vacuoles rather than from a defect in expression and assembly (Fig. 8) .
Although we did not observe significantly large amounts of Env incorporated into VEE-SHIV chimeric particles, a sufficient level of functional trimers was present to mediate binding and entry, as evidenced by the ability of VEE-SHIV chimeric particles to infect susceptible cells (Fig. 5) . To improve incorporation of Env into VEE-SHIV chimeric particles, the cytoplasmic tail was truncated. However, increased incorporation of Env into chimeric lentivirus-like particles did not correlate with increased titers of virus (see Fig. S2 in the supplemental material). This is consistent with the observation that one HIV Env trimer is sufficient to mediate binding and entry (57) . Maturation cleavage of gp160 Env to gp120 and gp41 appeared to be inefficient. This may be due to overexpression of gp160 from VEE RNA, limiting the availability of furin protease in the Golgi compartment that is not observed when Env is expressed from lentiviral message RNA. Alternatively, disruption of normal cellular secretory and protein processing pathways from VEE RNA replication may have contributed to the inefficient maturation cleavage of Env.
In the absence of specific RNA packaging signals within the chimeric virus genome, genomic RNA was incorporated into chimeric lentivirus-like particles at low levels, and subgenomic RNA accounted for the majority of the incorporated viral RNA. Subgenomic RNA is produced to higher levels than genomic RNA in alphavirus-infected cells (44, 50) and is consistent with Gag promiscuously packaging the most abundant RNA species for particle assembly. In addition, VEE-SHIV genomic RNA is significantly longer than lentiviral genomic RNA, and it may not be as efficiently incorporated into assembling particles as the alphaviral subgenomic RNAs. It was interesting that the subgenomic RNA contents of virus vaccine preparations produced from Gag-Env and Env-Gag were different. Incorporation of subgenomes may not be based solely on the size of the RNA since over 85% of viral RNA incorporated into Env-Gag particles was subgenome 1, and over 75% of viral RNA incorporated into Gag-Env particles was subgenome 2. Results from these experiments suggest that either subgenomic RNAs containing the env coding sequence were preferentially incorporated into chimeric vaccine particles or that gag coding sequences were excluded. Sequences in the 5= terminus of Gag may contribute to the packaging of HIV genomic RNA into assembling virions (27, 33) . In lentivirus genomes, these sequences are in the context of the 5= untranslated region (UTR) and packaging signal, which is not present in alphavirus subgenomic RNAs encoding Gag. The RNA structure of HIV genomic RNA is most likely different from the RNA structure of alphavirus subgenomic RNA encoding Gag; therefore, sequences in Gag that contribute to packaging HIV genomic RNA may not be in the right structural conformation to enhance packaging of subgenomic RNAs encoding Gag. Alternatively, the 5= end of Gag may contain signals sufficient for encapsidation of subgenomic RNA if gag is in the first position. However, gag in the second position may not be in the right conformation to promote encapsidation.
Two modifications were introduced into the prototype GagEnv chimera which increased the specific infectivity of the chimeric virus particles. First, a mutated protease was inserted in its normal relationship to Gag to promote particle maturation. Second, a putative VEE genome packaging element, derived from the VEE capsid protein, was added to the chimera in place of NC. Although the effects of adding the VEE capsid fragment at different sites in Gag were evaluated, this modification was the best choice in terms of both increased specific infectivity and placement of the protease at its normal site.
The chimeric virus vaccine particles produced after expression of unmodified Gag and Env from VEE RNA were morphologically similar to immature lentivirus particles, and Gag was incorporated into them as the uncleaved precursor. Remarkably, VEE-SHIV chimeric virus particles did not require SIV proteasemediated particle maturation in order to be at least minimally infectious. Lentivirus particle maturation involves the cleavage of the Gag polyprotein, resulting in a structural rearrangement of the viral particle to form a condensed core around the lentiviral nucleocapsid-RNA complexes, and is required for lentivirus infectivity (24, 53) . VEE-SHIV chimeric virus vaccine particles were able to release viral RNA into the cell cytoplasm and replicate, suggesting that cleavage maturation is not an absolute requirement for chimeric particle infectivity. However, the inclusion of SIV protease in the VEE-SHIV chimeric virus vaccine enhanced the infectivity of the particles, most likely by promoting particle maturation. Cleavage of Gag may have resulted in destabilization of the capsid shell, facilitating release of the RNA genome for more efficient replication. In addition, the inclusion of protease appeared to enhance the incorporation of Env into the chimeric virus particles. The matrix domain of Gag is reported to recognize the cytoplasmic tail domain of Env for inclusion in budding particles (12, 16) . Cleavage of Gag may have either exposed the Env binding domain or altered its conformation to facilitate inclusion of Env into the chimeric virus particles. Addition of the A28S mutation to attenuate protease activity decreased incorporation of Env to levels observed in the absence of protease (Fig. 8) . This further suggests that cleavage of Gag may have enhanced Env incorporation into chimeric particles. Curiously, increased Env incorporation did not correlate with improved infectivity of the chimeric virus preparations since we observed higher titers of GagPR(A28S)-Env particles than the titers observed for GagPREnv particles, and increased incorporation of Env by truncating the cytoplasmic tail did not correlate with improved titers compared to those of Gag-Env particles.
Although incorporation of putative genome packaging domains and modified protease independently improved the specific infectivity of chimeric virus particle preparations, both improvements were required for VEE-SHIV chimeric virus vaccine particles to propagate efficiently in cell culture. After several passages, the growth of the vaccine particles improved, suggesting that it is possible to evolve the vaccine particles for improved growth properties. Selection for chimeric virus particle growth in primate cell lines expressing the coreceptors may be advantageous for further improvement of the VEE-SHIV chimeras, prior to evaluating their efficacy as vaccine candidates in nonhuman primates.
The development of a live attenuated virus vaccine technology by creating chimeric viruses from heterologous virus families has several vaccine, therapeutic, and research applications. This technology may be beneficial for the creation of other live virus vaccines that may be considerably safer than live attenuated versions of viral pathogens such as rotavirus, flaviviruses, and filoviruses. Microbial or cancer immunogens may be incorporated into the chimeric virus particles for the development of cognate vaccines, or they may be used as directed delivery vehicles for therapeutic applications. As a research reagent, chimeric viruses may be used to study the role of structural proteins in viral attachment, entry and uncoating, and assembly, separate from their function in replication. Chimeric particles may also be useful reagents for generating antibodies against pathogens for diagnostic or passive immunization purposes or may be useful for the identification of neutralizing antibodies from serum.
